Summary After the market closed on September 25th, NKE reported Q1 FY2019 results and its share price pulled back ~4% in afterhours trading. The share price rebounded to close down only 1.25% on September 26th. The Federal Reserve increased rates 25 basis points on September 26th and a further increase is anticipated in December. If [...]
Brookfield Asset Management is a leading alternative asset manager, focused on investing in long-life, high-quality assets spanning over 30 countries globally. The business is organized into the following principal areas: Real Estate, Renewable Power, Infrastructure, and Infrastructure. I highly recommend you listen to Bruce Flatt's, CEO of Brookfield Asset Management, recent presentation at 'Talks at [...]
FedEx released its Q1 FY2019 results on September 17 and the stock pulled back ~5.5%. The stock price has subsequently recovered slightly but still remains in 'fairly valued' territory. Summary FDX released its Q1 2019 results on September 17th which reflected adjusted earnings of $3.46/share versus a forecast of $3.80/share. Revenue of $17.18B exceeded expectations [...]
Korn/Ferry International released its Q1 FY2019 results on September 6 and the stock pulled back ~24%. Results were negatively impacted by $106.6 million in trade name write-offs as part of an organizational restructuring which management had communicated to the investment community in June 2018. I view Mr. Market as having presented a buying opportunity in [...]
Summary Korn/Ferry released Q1 results on September 6 and reported a loss of $0.70/share. This included a one-time $106.6 million trade name write-off which management had communicated in June 2018. Other than the one-time write-off, results were positive and I view the price plunge has having brought shares into fair value territory. I view KFY [...]
Thermo Fisher Scientific's annual revenue of ~$23B is nearly double that reported in FY2011. This growth has been achieved through a series of acquisitions. While there are several tailwinds supporting management's 3 - 5% annual growth projections there are various short-term headwinds. This article looks at whether Thermo Fisher is currently fairly valued and whether [...]
Summary Thermo Fisher has a dominant position in the Medical Laboratories and Research segment of the healthcare industry with annual revenues of ~$23B. It has an industry-leading presence in high-growth / emerging markets; ~21% of its annual revenue is derived from these markets. There is the possibility that the Chinese government could ramp up their [...]
Summary In my March 22 article I indicated I viewed the pullback in ATD’s stock price as a window of opportunity to acquire shares in ATD at a favorable valuation; I acquired another 500 shares for the FFJ Portfolio. That article was followed up with my July 10 article in which I made a similar [...]
The Big 5 Canadian banks have recently released their Q3 results. In this article I compare the 5, 10, 15, and 20 year returns for all 5 and provide my opinion on the order of preference in which I would acquire shares. Summary A comparison of the 5, 10, 15, and 20 year returns [...]
Summary A comparison of the 5, 10, 15, and 20 year returns for the Big 5 Canadian banks shows a clear winner. The banks which have had significant US exposure for several years have fared much better than those which do not or which have only recently entered the US market. Despite the various headwinds/uncertainties [...]
